Loading...
Loading...
OMER| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | 0.0M |
| Operating Expense | 40.1M |
| Operating I/L | -40.1M |
| Other Income/Expense | -5.9M |
| Interest Income | 2.0M |
| Pretax | -46.0M |
| Income Tax Expense | -168.9M |
| Net Income/Loss | 128.7M |
Omeros Corporation is a biopharmaceutical company specializing in the discovery, development, and commercialization of small-molecule and protein therapeutics for various medical conditions. Their clinical programs include Narsoplimab (OMS721/MASP-2) for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA), immunoglobulin A nephropathy (IgAN), atypical hemolytic uremic syndrome (aHUS), and COVID-19. Additionally, they have programs for treating opioid and nicotine addiction, compulsive disorders, and movement disorders. Omeros Corporation also focuses on preclinical programs for age-related macular degeneration, cancer therapies, and G protein-coupled receptor targets for various disorders.
